Literature DB >> 21499327

Expression of purinergic P2X7 receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits.

Tomasz Grygorowicz1, Dorota Sulejczak, Lidia Struzynska.   

Abstract

Purinergic ionotropic P2X(7) receptor is widely distributed in brain. Strong evidence suggests that this receptor is related to inflammatory and neurodegenerative changes in many pathological states of central nervous system (CNS), including multiple sclerosis (MS). Experimental autoimmune encephalomyelitis (EAE) is the commonly used animal model of MS. In this study we investigate the expression of P2X(7)R protein in rat brain in the symptomatic phase of EAE (day 10 post immunization) and after reversion of neurological symptoms (day 20 p.i.). We found the increased level of P2X(7)R protein in brain homogenates of EAE rats in both examined time windows. Immunohistochemical study revealed enhanced receptor's immunoreactivity. Immunoblots done with isolated cellular brain fractions indicated that the P2X(7)R overexpression is related to synaptosomal fraction in the symptomatic phase and to the glial (GPV) fraction in the recovery phase of EAE. Concomitantly, we noticed overexpression of astroglial marker GFAP in brain homogenates and astroglial fraction (GPV), so as its enhanced immunoreactivity in brain sections (10 days p.i.) which did not decline to control values in the recovery phase, similarly to P2X(7)R expression. Results suggest the involvement of P2X(7)R-mediated signaling in the pathomechanisms of EAE with the possible relevance of astrocytic pool of cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21499327

Source DB:  PubMed          Journal:  Acta Neurobiol Exp (Wars)        ISSN: 0065-1400            Impact factor:   1.579


  12 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

2.  Contribution of pannexin1 to experimental autoimmune encephalomyelitis.

Authors:  Sarah E Lutz; Estibaliz González-Fernández; Juan Carlos Chara Ventura; Alberto Pérez-Samartín; Leonid Tarassishin; Hiromitsu Negoro; Naman K Patel; Sylvia O Suadicani; Sunhee C Lee; Carlos Matute; Eliana Scemes
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

3.  Emerging role of extracellular nucleotides and adenosine in multiple sclerosis.

Authors:  Marek Cieślak; Filip Kukulski; Michał Komoszyński
Journal:  Purinergic Signal       Date:  2011-07-27       Impact factor: 3.765

Review 4.  ATP as a multi-target danger signal in the brain.

Authors:  Ricardo J Rodrigues; Angelo R Tomé; Rodrigo A Cunha
Journal:  Front Neurosci       Date:  2015-04-28       Impact factor: 4.677

Review 5.  P2X and P2Y receptors—role in the pathophysiology of the nervous system.

Authors:  Kamila Puchałowicz; Maciej Tarnowski; Irena Baranowska-Bosiacka; Dariusz Chlubek; Violetta Dziedziejko
Journal:  Int J Mol Sci       Date:  2014-12-18       Impact factor: 5.923

6.  D-serine in the midbrain periaqueductal gray contributes to morphine tolerance in rats.

Authors:  Song Cao; Zhi Xiao; Mengjie Sun; Youyan Li
Journal:  Mol Pain       Date:  2016-05-12       Impact factor: 3.395

Review 7.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

Review 8.  Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.

Authors:  Júlia Leão Batista Simões; Julia Beatrice de Araújo; Margarete Dulce Bagatini
Journal:  Mol Neurobiol       Date:  2021-07-11       Impact factor: 5.590

Review 9.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

10.  Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence.

Authors:  Penghui Song; Jing Hu; Xijin Liu; Xuejun Deng
Journal:  Mol Med Rep       Date:  2019-04-30       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.